Ublituximab

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 114 publications

Uncoupling Relapse Reduction and Disability Progression: Evidence From Tolebrutinib Studies.

Uncoupling Relapse Reduction and Disability Progression: Evidence From Tolebrutinib Studies.

Journal: Neurology. Clinical practice

Published: May 11, 2026

Developing anti-CD20 molecules and B cell depletion in multiple sclerosis

Developing anti-CD20 molecules and B cell depletion in multiple sclerosis

Journal: Ideggyogyaszati szemle

Published: March 28, 2026

Efficacy and safety of monoclonal antibodies in the treatment of relapsing remitting multiple sclerosis: a systematic review.

Efficacy and safety of monoclonal antibodies in the treatment of relapsing remitting multiple sclerosis: a systematic review.

Journal: Journal of neurology

Published: February 18, 2026

Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study.

Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study.

Journal: JAMA neurology

Published: February 16, 2026

Translating B-Cell and Plasma-Cell Targeting from Oncology to Autoimmunity: Modalities, Quantitative Bridging, and a Development Roadmap.

Translating B-Cell and Plasma-Cell Targeting from Oncology to Autoimmunity: Modalities, Quantitative Bridging, and a Development Roadmap.

Journal: Clinical pharmacology and therapeutics

Published: January 31, 2026

The evolution and current status of anti-B-cell therapies in autoimmune neurologic diseases.

The evolution and current status of anti-B-cell therapies in autoimmune neurologic diseases.

Journal: Handbook of clinical neurology

Published: January 12, 2026

Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.

Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.

Journal: CNS drugs

Published: January 12, 2026

Impact of heme on the therapeutic efficacy of anti-CD20 antibodies.

Impact of heme on the therapeutic efficacy of anti-CD20 antibodies.

Journal: The Journal of biological chemistry

Published: January 07, 2026

Updated systematic literature review and network meta-analysis of cladribine tablets versus currently approved disease-modifying treatments for active relapsing-remitting multiple sclerosis.

Updated systematic literature review and network meta-analysis of cladribine tablets versus currently approved disease-modifying treatments for active relapsing-remitting multiple sclerosis.

Journal: Multiple sclerosis and related disorders

Published: December 19, 2025

Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis.

Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis.

Journal: Frontiers in immunology

Published: December 19, 2025

Disease-modifying treatment for multiple sclerosis in Poland in a European context: current practices and therapeutic strategies.

Disease-modifying treatment for multiple sclerosis in Poland in a European context: current practices and therapeutic strategies.

Journal: Neurologia i neurochirurgia polska

Published: December 18, 2025

Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis.

Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis.

Journal: Neurology and therapy

Published: December 16, 2025

Showing 1-12 of 114

Last Updated: 06/30/2026